The present invention provides a method for the synthesis of an injectable composition comprising a [18F]-labelled pyridaben derivative that is amenable to automation. In particular, the method of the present invention comprises a method of purification carried out by means of solid phase extraction (SPE) alone.
The invention relates to a method of preparing an [18F] radio-labelled compound, wherein the water content is controlled. Controlling the water content and the origin of the water within the reaction process has a significant effect on both the yield and the purity of the product of the radio-labelling process.
Provided is a method of preparing an aqueous ascorbic acid solution having a pH of 2.0 to 4.0, the method comprising: providing an initial aqueous solution of ascorbic acid and a base, wherein the initial solution has a pH of 5.0 to 8.0; and combining the initial solution with a second acid to obtain an ascorbic acid solution having a pH of 2.0 to 4.0. Also provided is the use of an aqueous ascorbic acid solution having a pH of 2.0 to 4.0 prepared by a described method as a radiostabiliser of a radio-labelled compound.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
C07B 59/00 - Introduction of isotopes of elements into organic compounds
The present invention concerns a HPLC separation method useful in the synthesis of [18F]-labelled compounds, including positron emission tomography (PET) tracers. The method of the invention addresses constraints of previous methods imposed by the needs of free 5 [18F]fluoride. The present invention provides a simplified process that enables rapid separation and analysis of free [18F]fluoride and chemical impurities in the synthesis of [18F]-labelled compounds.
According to one aspect of an exemplary embodiment of the disclosure, an imaging device or system, e.g., a mammography imaging system or device, includes a detector fixed on the device and a radiation source spaced from the detector. The device further includes a number of support structures moveably disposed on the device in positions between the detector and the radiation source. The support structures include attachment structures thereon that are each adapted to engage one or more components of the imaging device for use therewith, including but not limited to a compression paddle, a magstand and a positioned including a biopsy device thereon. The support structures can be engaged with any of the components in order to simplify the manner of attachment of the components to the device and to enable the components to readily be attached to the device in a variety of configurations.
A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
A61B 6/04 - Positioning of patientsTiltable beds or the like
A61B 6/50 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body partsApparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific clinical applications
A61B 6/46 - Arrangements for interfacing with the operator or the patient
The present invention relates to a sample processing bag (10) for use in a tissue disaggregation apparatus (200) for disaggregation of tissue therein. A clamp assembly 60 comprising a base support (70) and a clamp mechanism (72) is configured to retain the sample processing bag (10) adjacent to the base support (70) during a tissue disaggregation operation such that action of the tissue disaggregation apparatus 200 acts on the sample processing bag (10) to disaggregate any tissue therein.
The present invention relates to improved radiopharmaceutical compositions in sealed containers, where the container closure has an ETFE (ethylene-tetrafluoroethylene copolymer) coating. Also disclosed are kits for radiopharmaceutical preparation using the sealed containers, as well as methods of preparation of radiopharmaceuticals using the sealed containers.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
8.
APPARATUS, METHODS, AND MODELS FOR THERAPEUTIC PREDICTION
Methods, apparatus, systems, and articles of manufacture are disclosed for generation and application of models for therapeutic prediction and processing. An example apparatus includes a plurality of models to predict at least one of a) a toxicity in response to immunotherapy or b) an efficacy of the immunotherapy, the plurality of models trained and validated using data from previous patients; and processor circuitry. The processor circuitry is to execute the instructions to: accept an input, via an interface, of data associated with a first patient; generate, using at least one of the plurality of models, a prediction of at least one of: a) a toxicity occurring during immunotherapy according to a treatment plan for the first patient or b) an efficacy of the immunotherapy treatment plan for the first patient; and output a recommendation for the first patient with respect to the treatment plan.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
9.
MODEL GENERATION APPARATUS FOR THERAPEUTIC PREDICTION AND ASSOCIATED METHODS AND MODELS
Methods, apparatus, systems, and articles of manufacture are disclosed for generation and application of models for therapeutic prediction and processing. An example apparatus includes processing circuitry to at least: process input data pulled from a record to form a set of candidate features; train a first model and a second model using the set of candidate features; test the first model and the second model to compare performance of the first model and the second model; select at least one of the first model or the second model based on the comparison; store the selected first model and/or second model; and deploy the selected first model and/or second model to predict a likelihood of at least one of: a) a toxicity occurring due to immunotherapy according to a treatment plan or b) efficacy of the treatment plan for a patient.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
10.
MODEL GENERATION APPARATUS FOR THERAPEUTIC PREDICTION AND ASSOCIATED METHODS AND MODELS
Methods, apparatus, systems, and articles of manufacture are disclosed for generation and application of models for therapeutic prediction and processing. A balance of precision and recall can be applied to at least one of a toxicity-related model or an efficacy-related model to configure immunotherapy treatment of a patient and/or cohort of patients. Model output can be evaluated differently depending on a determine patient selection criterion to trigger different actions.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
The present invention relates to a shipping container for cryopreserved biological samples in which a cryopreserved sample can be maintained on arrival at its destination for a period of time, for example several months.
F25B 9/14 - Compression machines, plants or systems, in which the refrigerant is air or other gas of low boiling point characterised by the cycle used, e.g. Stirling cycle
F25D 3/10 - Devices using other cold materialsDevices using cold-storage bodies using liquefied gases, e.g. liquid air
F25D 19/00 - Arrangement or mounting of refrigeration units with respect to devices
The present invention provides a novel method for the preparation of 18F-fluoride (18F) for use in radiofluorination reactions. The method of the invention finds use especially in the preparation of 18F-labelled positron emission tomography (PET) tracers. The method of the invention is particularly advantageous where bulk solutions are prepared and stored in prefilled vials rather than being freshly prepared on the day of synthesis. Also provided by the present invention is a radiofluorination reaction which comprises the method of the invention, as well as a cassette for use in carrying out the method of the invention and/or the radiofluorination method of the invention on an automated radiosynthesis apparatus.
C07C 51/363 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by introduction of halogenPreparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by substitution of halogen atoms by other halogen atoms
Disclosed herein is a device in the form of a bung for insulating a container interior from the ambient environment, the bung comprising: a plurality of insulating segments; and one or more barriers for reflecting infrared radiation. Disclosed is: a method of preparing a shipping system for retaining a cryopreserved sample, the method comprising: loading a cryopreserved sample into a container such as a vacuum flask; and fitting the bung to the container to insulate the container interior from the ambient environment, and a method of cooling a container, such as a vacuum flask, for retaining cryopreserved samples to a desired temperature, the method comprising: cooling the container interior by pouring a cryogenic fluid such as liquid nitrogen into the container; and emptying the cryogenic fluid from the container, once the cooling has at least partially taken place.
B65D 81/38 - Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents with thermal insulation
B65D 39/00 - Closures arranged within necks or pouring openings or in discharge apertures, e.g. stoppers
The present invention provides a cassette for determining optimised solid phase extraction (SPE) purification conditions, wherein said cassette comprises:
(i) a flowpath comprising a first end and a second end; and
(ii) a plurality of valves oriented along said flowpath, wherein each of said plurality of valves is selectively fluidly connected to one of a number of components, wherein said components comprise:
(a) 1-5 composition vials;
(b) 1-3 SPE cartridges;
(c) 4-10 solvent vials;
(d) a water vial; and
(e) a transfer line.
The present invention provides a cassette for determining optimised solid phase extraction (SPE) purification conditions, wherein said cassette comprises:
(i) a flowpath comprising a first end and a second end; and
(ii) a plurality of valves oriented along said flowpath, wherein each of said plurality of valves is selectively fluidly connected to one of a number of components, wherein said components comprise:
(a) 1-5 composition vials;
(b) 1-3 SPE cartridges;
(c) 4-10 solvent vials;
(d) a water vial; and
(e) a transfer line.
The present invention also provides a method for determining optimised SPE purification conditions for a compound from a composition, the method comprising:
(i) provision of a cassette as defined in any of claims 1 to 7;
(ii) the cassette comprising a composition of the compound in said composition vial(s) or addition of such a composition to said crude reaction vial(s);
(iii) passing an aliquot of said composition into each of said 1-3 SPE cartridges;
(iv) passing a particular combination of aliquots of solvent from at least 4 of said 4-10 solvent vials into one or more of the SPE cartridges, wherein the solvent in each of said 4-10 solvent vials is either a different solvent or the same solvent at different concentration;
(v) eluting the compound to be purified from the or each SPE cartridge;
(vi) evaluating the eluted products of step (v); and
(vii) determining the optimised purification conditions by comparing the eluted products of step (v) from each cartridge and each solvent.
The present invention provides a radiopharmaceutical composition comprising the following four components: (i) a radio-labelled compound; (ii) ethanol; (iii) a stabilizer of the radio-labelled compound; and (iv) a cyclodextrin.
The present invention provides a radiopharmaceutical composition comprising the following four components: (i) a radio-labelled compound; (ii) ethanol; (iii) a stabilizer of the radio-labelled compound; and (iv) a cyclodextrin.
The present invention also provides a radiopharmaceutical composition comprising: (i) a radio-labelled compound; (ii) a stabilizer of the radio-labelled compound, wherein the stabilizer comprises: ascorbic acid, aspartic acid, cysteine, maleic acid, gentisic acid, glutathione, glutamic acid, mannitol, nicotinamide, calcium chloride, N-t-butyl-alpha-phenylnitrone (PBN), tartaric acid, para-aminobenzoic acid (pABA), chloride ions or salts or combinations thereof; and (iii) a cyclodextrin.
The invention relates to a method of preparing an [18F]radio-labelled compound, wherein the water content is controlled. Controlling the water content and the origin of the water within the reaction process has a significant effect on both the yield and the purity of the product of the radio-labelling process.
Provided is a method of preparing an aqueous ascorbic acid solution having a pH of 2.0 to 4.0, the method comprising: providing an initial aqueous solution of ascorbic acid and a base, wherein the initial solution has a pH of 5.0 to 8.0; and combining the initial solution with a second acid to obtain an ascorbic acid solution having a pH of 2.0 to 4.0. Also provided is the use of an aqueous ascorbic acid solution having a pH of 2.0 to 4.0 prepared by a described method as a radiostabiliser of a radio-labelled compound.
The invention relates to a method of preparing an [18F]radio-labelled compound, wherein the water content is controlled. Controlling the water content and the origin of the water within the reaction process has a significant effect on both the yield and the purity of the product of the radio-labelling process.
Provided is a method of preparing a vial containing an ascorbic acid solution, the method comprising: providing an aqueous solution of ascorbic acid and a base, wherein the solution has a pH of 5.0 to 8.0; degassing the solution with an inert gas; dispensing the solution into a vial; degassing the vial headspace with an inert gas; and sealing the vial. Also provided is a vial containing: an aqueous solution of ascorbic acid and a base, wherein the solution has a pH of 5.0 to 8.0; and an inert gas.
Disclosed herein is a device in the form of a bung for insulating a container interior from the ambient environment, the bung comprising: a plurality of insulating segments; and one or more barriers for reflecting infrared radiation. Disclosed is: a method of preparing a shipping system for retaining a cryopreserved sample, the method comprising: loading a cryopreserved sample into a container such as a vacuum flask; and fitting the bung to the container to insulate the container interior from the ambient environment, and a method of cooling a container, such as a vacuum flask, for retaining cryopreserved samples to a desired temperature, the method comprising: cooling the container interior by pouring a cryogenic fluid such as liquid nitrogen into the container; and emptying the cryogenic fluid from the container, once the cooling has at least partially taken place.
A47J 41/02 - Vacuum-jacket vessels, e.g. vacuum bottles
F25D 17/04 - Arrangements for circulating cooling fluidsArrangements for circulating gas, e.g. air, within refrigerated spaces for circulating gas, e.g. by natural convection
The present invention concerns a HPLC separation method useful in the synthesis of [18F]-labelled compounds, including positron emission tomography (PET) tracers. The method of the invention addresses constraints of previous methods imposed by the needs of free 5 [18F]fluoride. The present invention provides a simplified process that enables rapid separation and analysis of free [18F]fluoride and chemical impurities in the synthesis of [18F]-labelled compounds.
The present invention concerns a HPLC separation method useful in the synthesis of [18F]-labelled compounds, including positron emission tomography (PET) tracers. The method of the invention addresses constraints of previous methods imposed by the needs of free 5 [18F]fluoride. The present invention provides a simplified process that enables rapid separation and analysis of free [18F]fluoride and chemical impurities in the synthesis of [18F]-labelled compounds.
A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to radiotracer compositions which comprises 18F-labelled c-Met binding peptides. The invention provides said compositions, as well as associated automated methods of preparation and cassettes.
Disclosed is a device (100, 200) for the disaggregation of tissue samples into individual cells or cell clumps in a closed flexible tissue sample bag (10); the device including two or more resilient feet (134/136, 234/236) which tread sequentially a tissue sample bag receiving area (148,248). Also disclosed is a heat transfer plate (150, 250) for transferring heat energy to or from the area (148,248), the plate having one plate surface (151,251) adjacent the area (148,248) and an opposing surface (152,252) exposed to external thermal influence which faces away from the area (148,248). Further disclosed is a tissue sample receiving bag (10) comprising one or more flexible plastics cavity (12) formed from two layers of the plastics sealed around their edges to form a generally rectilinear periphery with the cavity or cavities (12) within the periphery, and at one side of the periphery is formed one or more sealable access ports (16). One part of the bag is left unsealed to provide a tissue sample receiving opening.
A method of labelling biological molecules with 18F, via attachment of fluorine to a metal complex, where the metal complex is conjugated to the biological molecule. The invention highlights the incorporation of hydrogen bonding (H-bonding) into the metal complex scaffold, and how this can be utilized to improve the kinetics of fluoride incorporation. Also provided are pharmaceutical compositions, kits and methods of in vivo imaging.
C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic Table
C07D 255/02 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups not condensed with other rings
The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to a method of purifying a radiotracer which comprises 18F-labelled aminoxy-functionalised biological targeting moiety. The invention provides radioprotectant-containing radiopharmaceutical compositions of the tracers, as well as associated automated methods and cassettes.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
B01D 15/20 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
B01D 15/22 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the construction of the column
B01D 15/32 - Bonded phase chromatography, e.g. with normal bonded phase, reversed phase or hydrophobic interaction
B01D 15/42 - Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
A device and a method for mixing a fluid in a specimen bag is provided herein. In one embodiment, the device includes a mechanism for creating a first vortex and a second vortex. The first vortex is on a first side of a bag containing the fluid, and the second vortex is on a second side of the bag. The mechanism includes a first inflatable airbag and a second inflatable airbag. The first inflatable airbag is configured to create the first vortex when inflated and the second inflatable airbag is deflated. The second inflatable airbag is configured to create the second vortex when inflated and the first inflatable airbag is deflated.
B01F 25/42 - Static mixers in which the mixing is affected by moving the components jointly in changing directions, e.g. in tubes provided with baffles or obstructions
B01F 31/55 - Mixers with shaking, oscillating, or vibrating mechanisms the materials to be mixed being contained in a flexible bag submitted to periodical deformation
B01F 35/513 - Flexible receptacles, e.g. bags supported by rigid containers
The present invention provides a cassette for determining optimised solid phase extraction (SPE) purification conditions, wherein said cassette comprises: (i) a flowpath comprising a first end and a second end; and (ii) a plurality of valves oriented along said flowpath, wherein each of said plurality of valves is selectively fluidly connected to one of a number of components, wherein said components comprise: (a) 1-5 composition vials; (b) 1-3 SPE cartridges; (c) 4-10 solvent vials; (d) a water vial; and (e) a transfer line. The present invention also provides a method for determining optimised SPE purification conditions for a compound from a composition, the method comprising: (i) provision of a cassette as defined in any of claims 1 to 7; (ii) the cassette comprising a composition of the compound in said composition vial(s) or addition of such a composition to said crude reaction vial(s); (iii) passing an aliquot of said composition into each of said 1-3 SPE cartridges; (iv) passing a particular combination of aliquots of solvent from at least 4 of said 4-10 solvent vials into one or more of the SPE cartridges, wherein the solvent in each of said 4-10 solvent vials is either a different solvent or the same solvent at different concentration; (v) eluting the compound to be purified from the or each SPE cartridge; (vi) evaluating the eluted products of step (v); and (vii) determining the optimised purification conditions by comparing the eluted products of step (v) from each cartridge and each solvent.
The present invention provides a cassette for determining optimised solid phase extraction (SPE) purification conditions, wherein said cassette comprises: (i) a flowpath comprising a first end and a second end; and (ii) a plurality of valves oriented along said flowpath, wherein each of said plurality of valves is selectively fluidly connected to one of a number of components, wherein said components comprise: (a) 1-5 composition vials; (b) 1-3 SPE cartridges; (c) 4-10 solvent vials; (d) a water vial; and (e) a transfer line. The present invention also provides a method for determining optimised SPE purification conditions for a compound from a composition, the method comprising: (i) provision of a cassette as defined in any of claims 1 to 7; (ii) the cassette comprising a composition of the compound in said composition vial(s) or addition of such a composition to said crude reaction vial(s); (iii) passing an aliquot of said composition into each of said 1-3 SPE cartridges; (iv) passing a particular combination of aliquots of solvent from at least 4 of said 4-10 solvent vials into one or more of the SPE cartridges, wherein the solvent in each of said 4-10 solvent vials is either a different solvent or the same solvent at different concentration; (v) eluting the compound to be purified from the or each SPE cartridge; (vi) evaluating the eluted products of step (v); and (vii) determining the optimised purification conditions by comparing the eluted products of step (v) from each cartridge and each solvent.
The present invention provides a radiopharmaceutical composition comprising the following four components: (i) a radio-labelled compound; (ii) ethanol; (iii) a stabilizer of the radio-labelled compound; and (iv) a cyclodextrin. The present invention also provides a radiopharmaceutical composition comprising: (i) a radio-labelled compound; (ii) a stabilizer of the radio-labelled compound, wherein the stabilizer comprises: ascorbic acid, aspartic acid, cysteine, maleic acid, gentisic acid, glutathione, glutamic acid, mannitol, nicotinamide, calcium chloride, N-t-butyl-alpha-phenylnitrone (PBN), tartaric acid, para-aminobenzoic acid (pABA), chloride ions or salts or combinations thereof; and (iii) a cyclodextrin.
The present invention provides a radiopharmaceutical composition comprising the following four components: (i) a radio-labelled compound; (ii) ethanol; (iii) a stabilizer of the radio-labelled compound; and (iv) a cyclodextrin. The present invention also provides a radiopharmaceutical composition comprising: (i) a radio-labelled compound; (ii) a stabilizer of the radio-labelled compound, wherein the stabilizer comprises: ascorbic acid, aspartic acid, cysteine, maleic acid, gentisic acid, glutathione, glutamic acid, mannitol, nicotinamide, calcium chloride, N-t-butyl-alpha-phenylnitrone (PBN), tartaric acid, para-aminobenzoic acid (pABA), chloride ions or salts or combinations thereof; and (iii) a cyclodextrin.
Medical apparatus and equipment for the collection,
processing, analysis and preservation of biological samples
such as blood and cellular products; disposable medical
containers for the collection and preservation and transport
of blood and cellular products; kits comprising disposable
bags for the collection, processing, analysis and
preservation of biological samples such as blood and
cellular products; bags and boxes for collecting and
preserving biological samples such as blood and cellular
products.
18F-fluoride (18F) for use in radiofluorination reactions. The method of the invention finds use especially in the preparation of 18F-labelled positron emission tomography (PET) tracers. The method of the invention is particularly advantageous where bulk solutions are prepared and stored in prefilled vials rather than being freshly prepared on the day of synthesis. Also provided by the present invention is a radiofluorination reaction which comprises the method of the invention, as well as a cassette for use in carrying out the method of the invention and/or the radiofluorination method of the invention on an automated radiosynthesis apparatus.
18F]-labelled pyridaben derivative that is amenable to automation. In particular, the method of the present invention comprises a method of purification carried out by means of solid phase extraction (SPE) alone.
The present approach relates to determining a reference value based on image data that includes a non-occluded vascular region (such as the ascending aorta in a cardiovascular context). This reference value is compared on a pixel-by pixel basis with the CT values observed in the other vasculature regions. With this in mind, and in a cardiovascular context, the determined FFR value for each pixel is the ratio of CT value in the vascular region of interest to the reference CT value.
A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
18F]-labelled pyridaben derivative that is advantageous over prior methods. In particular, the method of the present invention comprises a method of radiosynthesis that permits a more facile purification using solid phase extraction (SPE).
The present invention relates a method of monitoring an automated radiosynthesizer during a run and the radiosynthesizer having a number of individual activity detectors operably associated therewith. The method comprises the steps of recording S10 activity data from each activity detector; accessing S20 historic data from a data storage; detecting S30 precursor of yield drop in the recorded activity data based on the historic data; predicting (S40 yield when synthesizing a tracer with the radiosynthesizer based on the detected precursor of yield drop; and initiating S50 actions related to a level of predicted yield.
Medical apparatus and equipment for the collection, processing, analysis and preservation of biological samples such as blood and cellular products; disposable medical containers for the collection and preservation and transport of blood and cellular products; kits comprising disposable bags for the collection, processing, analysis and preservation of biological samples such as blood and cellular products; bags and boxes for collecting and preserving biological samples such as blood and cellular products; none of the aforementioned goods consisting of apparatus, equipment or reagents used in the process of electrophoresis, mass spectrometry and/or screening of autoimmune and infectious diseases
Disclosed is a bioprocessing system comprising apparatus (200) including a centrifugal separation housing (210) having a temperature controllable compartment (215) for removably accepting a separation chamber (50), the apparatus further comprising at least one mixing station (250) for supporting one or more fluid storage vessels (10, 20, 30, 40), the station including a temperature controllable area (252) for increasing or decreasing the temperature of the contents of the or each supported vessel. The system further includes a disposable fluidic arrangement (100) including a centrifugal separation chamber (50) removably mountable within the compartment (215) and having one or more ports (52) allowing fluid ingress into, or egress out of the chamber, via the one or more ports in use, said ports being in fluid communication with one or more of said fluid storage vessels via fluid conduits (12, 22, 32, 42) and via one or more valve arrangement.
The invention discloses a sterile syringe (100) comprising a barrel (1) having internal surfaces (2), a plunger (3) movable within the barrel, a non-sliding seal (7) between the barrel and the plunger defining a sealed volume (8) and at least one filter (9) allowing only filtered gases to enter the sealed volume such that the syringe maintains its sterility even after several uses. The filters could be positioned on different locations on the syringe like on the non-sliding seal, the barrel, the barrel flange or the plunger handle.
Disclosed is a device for use in freezing at least part of a biological sample in a receptacle, e.g. a vial or a cryopreservation bag, the device comprising: a base; and a receptacle holder comprising: a first part configured to, with the receptacle held by the receptacle holder during cooling of the base using a cooler device, withdraw heat energy from a first portion of the receptacle at a first heat withdrawal rate; and a second part configured such that, with the receptacle held by the receptacle holder during cooling of the base using the cooler device, a second heat withdrawal rate of heat energy withdrawal from a second portion of the receptacle via the second part is less than the first heat withdrawal rate. A temperature gradient may be established in the sample to enable progressive solidification to occur in the sample. A receptable for use in freezing a biological sample, and a freezing method are disclosed also.
Disclosed is a computer-implemented method comprising: obtaining first data indicative of electric power supplied to a cooling apparatus during a cooling operation on a biological sample, the cooling operation having a given cooling condition; obtaining second data associated with a reference cooling condition; determining, based on the first data and the second data, whether the given cooling condition has a predetermined relationship with the reference cooling condition; and in response to a determination, by the determining, that the given cooling condition has the predetermined relationship with the reference cooling condition, outputting a control signal. The given cooling condition for the “live” data cooling operation may thus be validated against a reference cooling condition.
G05B 19/4155 - Numerical control [NC], i.e. automatically operating machines, in particular machine tools, e.g. in a manufacturing environment, so as to execute positioning, movement or co-ordinated operations by means of programme data in numerical form characterised by programme execution, i.e. part programme or machine function execution, e.g. selection of a programme
Containers (100) for cryopreserved biological samples (102) may include an insulated housing including a cavity (108) for containing at least one cryopreserved biological sample; and a sealed reservoir (106) at least partly surrounding the cavity, the sealed reservoir including liquified gas (120) such as liquified air, the gas being kept largely liquified by a heat transfer engine (112) such as a Stirling cryocooler. A valve (114) may be provided to function as both a pressure relief valve and an inlet valve. The inlet valve may be coupled to a sensor (122) for sensing a volume of liquified gas within the sealed reservoir. The container may further include a heat exchanger (116) coupled to the heat engine and extending into the sealed reservoir.
F17C 3/08 - Vessels not under pressure with provision for thermal insulation by vacuum spaces, e.g. Dewar flask
F25B 9/14 - Compression machines, plants or systems, in which the refrigerant is air or other gas of low boiling point characterised by the cycle used, e.g. Stirling cycle
F25D 3/10 - Devices using other cold materialsDevices using cold-storage bodies using liquefied gases, e.g. liquid air
F25D 11/04 - Self-contained movable devices associated with refrigerating machinery, e.g. domestic refrigerators specially adapted for storing deep-frozen articles
Disclosed is a device (100, 200) for the disaggregation of tissue samples into individual cells or cell clumps in a closed flexible tissue sample bag (10); the device including two or more resilient feet (134/136, 234/236) which tread sequentially a tissue sample bag receiving area (148,248). Also disclosed is a heat transfer plate (150, 250) for transferring heat energy to or from the area (148,248), the plate having one plate surface (151,251) adjacent the area (148,248) and an opposing surface (152,252) exposed to external thermal influence which faces away from the area (148,248). Further disclosed is a tissue sample receiving bag (10) comprising one or more flexible plastics cavity (12) formed from two layers of the plastics sealed around their edges to form a generally rectilinear periphery with the cavity or cavities (12) within the periphery, and at one side of the periphery is formed one or more sealable access ports (16). One part of the bag is left unsealed to provide a tissue sample receiving opening.
A medical system useful in the determination of future disease progression in a subject. More specifically the present invention applies machine learning techniques to aid prediction of disease pathology and clinical outcomes in subjects presenting with symptoms of cognitive decline and to expedite clinical development of novel therapeutics.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Radiopharmaceuticals; markers for diagnostic use;
pharmaceutical and veterinary products; pharmaceutical
preparations for human and veterinary use; biological
preparations for medical use; diagnostic products for
medical use; chemical preparations for medical use; food
supplements and nutritional supplements for medical use;
dietetic food and substances for medical and pharmaceutical
use; homeopathic and plant therapy compositions; sanitary
products for medical purposes; medicinal baths; dietetic
beverages for medical use; chemical reagents for medical
use, namely biomarkers; products for personal hygiene for
medical purposes; plasters, materials for dressings;
surgical and medical dressings. Medical devices for diagnostic use for administering
contrast media; medical diagnostic instruments; testing
instruments for use in medical diagnosis; diagnostic
apparatus for medical use; medical and veterinary apparatus
and instruments; surgical apparatus and instruments;
instruments for collection of human body fluids; kits
containing medical instruments; containers for medical
samples; tubes for surgical applications; container
holders for samples; tubes for medical applications;
syringes for medical use; syringe needles for medical use;
containers especially adapted for depositing syringes. Training services in the following fields: health,
pharmaceutical and medical research, pharmaceutical and
medical development; publication of books and texts other
than advertising texts in the pharmaceutical, medical and
health fields; arranging and conducting of colloquiums,
conferences, congresses, seminars in the pharmaceutical,
medical and health fields; education in the pharmaceutical,
medical and health fields. Development of pharmaceutical products; pharmaceutical
research and development; testing on pharmaceutical
products; carrying out clinical trials for pharmaceutical
products; scientific research regarding medicine;
bio-informatic, chemical and biological analysis; research
in chemistry, cosmetology, biology, bacteriology, nutrition,
biotechnology; biological and bio-informatic research
services in the field of chemical, biological and
pharmaceutical products; software design and development in
the field of pharmaceutical, health and medical research;
Providing medical and scientific research information in the
field of pharmaceutical products and clinical trials;
research on chemical reagents for medical use, namely
biomarkers; design of databases in the field of
pharmaceutical research and development, medicine, genetics
and clinical trials. Pharmaceutical services; pharmacy advice; information and
advisory services relating to pharmaceutical products;
medical services; medical information services; providing
medical information; information services on the treatment
of diseases via an awareness program; providing information
with respect to pharmaceuticals.
A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
Disclosed is a centrifugal separation chamber (100) rotatable about an axis (AR) and having a variable volume separation space (116) therewithin and a port (102) in fluid communication with the volume for filling and emptying the volume, the chamber including a relatively rigid portion (104) proximal to the port which has walls defining a part of the volume and arranged to provide reducing dimensions of the volume toward the port, the chamber further including a flexible portion (106) distal to the port for providing said variable volume, the flexible portion including a mechanical interface (110) for transmitting movement to the flexible portion to cause said variable volume.
The present invention relates to methods and apparatus for the cryopreservation of biological samples involving a density assisted vitrification wherein a sample of biological material in a cryopreservation agent is cooled from its top surface, causing an ice layer to form thereon. As cooling continues the ice layer grows downwards through the sample to provide a cryoprotectant and biological material rich layer below the ice layer that undergoes vitrification as cooling continues to below the glass transition temperature.
The present invention relates to methods of cryopreservation and compositions for use in such methods where the methods utilise non-Newtonian fluid properties of the cryopreservation medium to modulate the viscosity of that medium to deliver an improved cryopreservation process.
An adaptive template image for registering a PET or a SPECT image includes a template image model including variability of values for each voxel in a template image according to one or more control parameters.
The present invention relates to a system for separating biological fluids ink components that makes use of a hollow centrifugal processing chamber of variable volume. The system is a functionally closed centrifugation chamber that extracts sub-components of a biological fluid according to their density and size, such as platelets, plasma or red cells from whole blood.
An image quality control system is disclosed. The example system includes an artificial intelligence modeler to process image data and metadata from patient data to generate first feature(s)from the image data and to parse the metadata to identify study information. The example system includes a computer vision processor to identify second feature(s)in the image data. The example system includes a results evaluator to compare the first feature(s)and second feature(s)to generate a comparison and to evaluate the comparison,first feature(s), and second feature(s)with respect to the study information to generate an evaluation. The example system includes a quality controller to compare the evaluation to quality criterion(-ia)to produce an approval or rejection of the patient data, the approval to trigger release of the patient data and the rejection to deny release of the patient data.
An image quality control system is disclosed. The example system includes an artificial intelligence modeler to process image data and metadata from patient data to generate first feature(s) from the image data and to parse the metadata to identify study information. The example system includes a computer vision processor to identify second feature(s) in the image data. The example system includes a results evaluator to compare the first feature(s) and second feature(s) to generate a comparison and to evaluate the comparison, first feature(s), and second feature(s) with respect to the study information to generate an evaluation. The example system includes a quality controller to compare the evaluation to quality criterion(-ia) to produce an approval or rejection of the patient data, the approval to trigger release of the patient data and the rejection to deny release of the patient data.
G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
A flexible bag (1; 101; 201) comprising a component (3; 103; 203) inside the bag, wherein said flexible bag comprises a receiving device (5; 105; 205) provided in a wall (7; 107; 207) of the flexible bag, wherein said component (3; 103; 203) and said receiving device (5; 105; 205) are configured for being connectable to each other for keeping the component substantially stationary within the flexible bag when so connected.
Disclosed is an in-process cell monitoring device comprising: a flow channel having at least one inlet and at least one outlet exposeable to a cell culture; a microscope positionable to view the contents of a region of the channel; and a computer operable at least to count any cells in the region, providing a closed fluid circuit for cell monitoring. Disclosed also is a bioreactor including a cell culture volume, and an in-process cell monitoring device, said device comprising: a flow channel having at least one inlet and at least one outlet each in fluid communication with the volume, of sufficient cross-sectional area to allow fluids to drain from the inlet to the outlet; and a microscope positionable to view the contents of a region of the channel, and also A method for monitoring a cell culture including determining cell density.
A bioreactor vessel incudes a first compartment configured to receive a suspension comprising cells and a cell culture medium, for use in a cell processing operation, a second compartment for receiving an overflow of the cell culture medium from the first compartment, and an overflow separating the first compartment from the second compartment, the overflow being configured to maintain a level of the cell culture medium in the first compartment.
An equatorial anthropic radiation source and a method of making an equatorial anthropic radiation source are described. The radiation source is useful in diagnostic imaging applications in healthcare or other industries (e.g. computerized three-dimensional segmental imaging; Crompton scattering imaging techniques; radiation detector check and calibration, in particular CdZnTe detectors commonly used in medical imaging).
G21G 4/08 - Radioactive sources other than neutron sources characterised by constructional features specially adapted for medical applications
G21G 1/00 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes
G21G 1/02 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes in nuclear reactors
G21G 4/06 - Radioactive sources other than neutron sources characterised by constructional features
G21G 1/06 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes outside of nuclear reactors or particle accelerators by neutron irradiation
B29C 39/00 - Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressureApparatus therefor
B29K 63/00 - Use of epoxy resins as moulding material
A device for the processing and separation of biological fluids into components comprises a hollow centrifugal processing chamber (10) fitted with an inlet/outlet head (20) and preferably with an axially movable piston (18). The inlet/outlet head has two separate inlets/outlets, for instance an axial inlet (29) and a lateral outlet (40). The processing chamber (1) is fitted with an internal flow guide (30) enabling operation of the device in a continuous processing mode wherein biological fluid to be processed is continuously intaken by say the axial inlet (29) and at the same time processed components are continuously removed via say the lateral outlet (40). The continuous processing flow can be driven by an external peristaltic pump (59) and/or by axial displacement of a piston (18) in the chamber (10).
A cellbag bioreactor includes a stacked filter providing multiple porous membranes to define a filter cavity. Additionally, a filter within the cellbag bioreactor may be tethered so as to help maintain each membrane of a filter wetted during bioreactor operations.
A bioreactor vessel includes a body having upper and lower ends and a hollow interior cavity formed in the body, the interior cavity located between the upper and lower ends, the interior cavity being configured to receive biomaterials for processing. The interior cavity includes a lower boundary that is angled toward the lower end of the body such that the vessel may be tilted to allow biomaterials within the interior cavity to be extracted and concentrated and/or washed without the need for a separate bioprocessing device.
Systems and methods for tracking and management of a distributed ledger including information for a batch of radiopharmaceutical material are disclosed. Certain examples provide a computer-implemented method of managing radiopharmaceutical material including tracking, using at least one processor, a status of a batch of radiopharmaceutical material, the status to include a type, a quantity, and a timestamp associated with the batch of radiopharmaceutical material;generating a record in a first copy of a distributed ledger using the type, quantity, and timestamp associated with the batch of radiopharmaceutical material;updating the record based on at least one of usage of the batch of radiopharmaceutical material, resale of at least a portion of the batch of radiopharmaceutical material, and decay of the batch of radiopharmaceutical material; and sharing the record with a second copy of the distributed ledger.
Apparatus, non-transitory computer-readable storage medium, and computer-implemented method for distributed ledger management of nuclear medicine products
Systems and methods for tracking and management of a distributed ledger including information for a batch of radiopharmaceutical material are disclosed. Certain examples provide a computer-implemented method of managing radiopharmaceutical material including tracking, using at least one processor, a status of a batch of radiopharmaceutical material, the status to include a type, a quantity, and a timestamp associated with the batch of radiopharmaceutical material; generating a record in a first copy of a distributed ledger using the type, quantity, and timestamp associated with the batch of radiopharmaceutical material; updating the record based on at least one of usage of the batch of radiopharmaceutical material, resale of at least a portion of the batch of radiopharmaceutical material, and decay of the batch of radiopharmaceutical material; and sharing the record with a second copy of the distributed ledger.
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
G06Q 30/06 - Buying, selling or leasing transactions
Disclosed is a method for the production of a porous polymer membrane suitable for liquid filtration or analyte capture, comprising the steps of: providing a flowable composition (100) on a substrate (220) the composition including at least: photo-activatable monomer molecules, photo activation initiator molecules and photo- activation quencher molecules; providing one or more pulses (L) of laser light at at least one focal point in the composition of sufficient energy to locally polymerise the composition; moving the or each focal point relative to the previously polymerised composition in a continuous or stepwise predetermined manner to a multiplicity of further positions;and repeating the pulse(s) at those further positions such that a three dimensional matrix of the composition is polymerised leaving unpolymerized areas of a size equivalent to conventional polymer membrane pores.
Apparatus, systems, and methods for tracking and management of bioprocess and/or other sterile product inventory are disclosed. An example apparatus includes: a communication interface to receive a message from a radiofrequency identification circuit associated with a product via an antenna at a location; a keycode verifier to verify a keycode from the message as authentic and associated with the product; a certificate generator to provide, when the keycode is verified, a certificate for the product, the certificate to be sent from a cloud-based server to a local computing device at the location to enable use of the product; an inventory predictor to predict, based on an identification of the product and usage information for the product and/or the location, an exhaustion of the product at the location; an output generator to trigger an order of the product when the exhaustion of the product at the location is predicted.
A remote system for monitoring and controlling one or more devices for use in the cryogenic processing of a sample is provided. A remote server capable of transmitting freezing profile data to one or more freezers, transmitting transportation profile data to one or more transportation devices, and transmitting thawing profile data to one or more thawing devices. The remote server is also capable of receiving detected data from the one or more freezers relating to the freezing of a sample in accordance with the freezing profile data, receiving detected data from the one or more transportation devices relating to the transportation of a sample in accordance with the transportation profile data, and receiving detected data from the one or more thawing machines relating to the thawing of a sample in accordance with the thawing profile data.
B01L 7/00 - Heating or cooling apparatusHeat insulating devices
H04L 67/125 - Protocols specially adapted for proprietary or special-purpose networking environments, e.g. medical networks, sensor networks, networks in vehicles or remote metering networks involving control of end-device applications over a network
77.
Systems and methods for remotely monitoring the cryogenic processing of samples
A remote system for monitoring and controlling one or more devices for use in the cryogenic processing of a sample is provided. A remote server capable of transmitting freezing profile data to one or more freezers, transmitting transportation profile data to one or more transportation devices, and transmitting thawing profile data to one or more thawing devices. The remote server is also capable of receiving detected data from the one or more freezers relating to the freezing of a sample in accordance with the freezing profile data, receiving detected data from the one or more transportation devices relating to the transportation of a sample in accordance with the transportation profile data, and receiving detected data from the one or more thawing machines relating to the thawing of a sample in accordance with the thawing profile data.
B01L 7/00 - Heating or cooling apparatusHeat insulating devices
H04L 67/125 - Protocols specially adapted for proprietary or special-purpose networking environments, e.g. medical networks, sensor networks, networks in vehicles or remote metering networks involving control of end-device applications over a network
78.
Systems and methods for remotely monitoring the cryogenic processing of samples
A remote system for monitoring and controlling one or more devices for use in the cryogenic processing of a sample is provided. A remote server capable of transmitting freezing profile data to one or more freezers, transmitting transportation profile data to one or more transportation devices, and transmitting thawing profile data to one or more thawing devices. The remote server is also capable of receiving detected data from the one or more freezers relating to the freezing of a sample in accordance with the freezing profile data, receiving detected data from the one or more transportation devices relating to the transportation of a sample in accordance with the transportation profile data, and receiving detected data from the one or more thawing machines relating to the thawing of a sample in accordance with the thawing profile data.
B01L 7/00 - Heating or cooling apparatusHeat insulating devices
H04L 67/125 - Protocols specially adapted for proprietary or special-purpose networking environments, e.g. medical networks, sensor networks, networks in vehicles or remote metering networks involving control of end-device applications over a network
The present invention relates to a shipping container for cryopreserved biological samples in which a cryopreserved sample can be maintained on arrival at its destination for a period of time, for example several months.
F25B 9/14 - Compression machines, plants or systems, in which the refrigerant is air or other gas of low boiling point characterised by the cycle used, e.g. Stirling cycle
F25D 3/10 - Devices using other cold materialsDevices using cold-storage bodies using liquefied gases, e.g. liquid air
F25D 19/00 - Arrangement or mounting of refrigeration units with respect to devices
F25D 3/14 - Devices using other cold materialsDevices using cold-storage bodies using solidified gases, e.g. carbon-dioxide snow portable, i.e. adapted to be carried personally
The present invention provides a process to enhance the productivity such as yield of radioactive fluorine labeled flutemetamol.
in which the above step (a) is carried out at an internal temperature of reaction solution of 140° C. or higher.
C07D 277/66 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
C07B 59/00 - Introduction of isotopes of elements into organic compounds
Apparatus are provided for preventing the formation of ice crystals in a biological sample containing a non-Newtonian fluid as a cryopreservation medium. The apparatus may be used to prevent ice formation during cryopreservation of biological samples, or during warming of cryopreserved biological samples, by changing the viscosity of the non-Newtonian fluid. The apparatus (200) comprises a housing (202) for a container (212) containing the biological sample (214) and the non-Newtonian fluid, and a device (204) for inducing a change in viscosity of the cryopreservation medium. The change in viscosity may be increased by inducing shear thickening of the cryopreservation medium, or the change in viscosity may be decreased by inducing shear thinning of the cryopreservation medium. Possible viscosity-changing devices comprise a tapping device, a piston, a rotating device, a compression device, a sound generating device, a permanent magnet or a electromagnetic field generating device. The apparatus may further include a temperature control device.
The present invention relates to a method for conditioning reversed phase SPE cartridges that provides certain advantages compared with known such methods. The method of the invention finds particular use in the automated synthesis of radiolabeled compounds where SPE is used for example in the purification steps.
B01D 15/20 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
B01D 15/32 - Bonded phase chromatography, e.g. with normal bonded phase, reversed phase or hydrophobic interaction
C07B 59/00 - Introduction of isotopes of elements into organic compounds
The present invention provides a system for evaporating a radioactive fluid, a method for the synthesis of a radiolabelled compound including this system, and a cassette for the synthesis of a radiolabelled compound comprising this system. The present invention provides advantages over known methods for evaporation of a radioactive fluid as it reduces drastically the amount of radioactive gaseous chemicals that are released in the hot cell. It is gentler and more secure compared to the known process and provides access to radiosyntheic processes that may not been acceptable for safety reasons related to release of volatile radioactive gases during evaporation. In addition, the process yields are higher because the radioactive volatiles are labelled intermediate species.
C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
G21G 1/00 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes
Disclosed is a product and method for sampling cells from a bioreactor, for the purposes of determining the cell count or to remove a sample and retain sterility of the sample for quality control (QC) assessment during a cell expansion in a bioreactor using vacuum tubes in combination with a sampling manifold (1) comprising:a primary fluid conduit (2);a connection port (3) positioned at one end of said fluid conduit (2) comprising means (4) for selective fluid connection of the interior of said fluid conduit (2) to the interior of a sampling reservoir (5); and a plurality of sampling ports (6a-e) disposed along said fluid conduit (2); wherein each of said plurality of sampling ports(6a-e) comprises means (7a-e) for selective fluid connection with an outlet (8a-e) adapted to connect to means (9) to permit exclusively unidirectional fluid flow from said primary fluid conduit.
A process for the sequential processing of opaque and transparent biological fluids such as whole blood, apheresis blood, bone marrow blood, umbilical cord blood, buffy coat or cultured cells by processing steps in a hollow cylindrical centrifugal processing chamber (300) which is part of a disposable set. At least three different procedures selected from washing, incubation, transduction, separation, density gradient separation, dilution and volume adjustment are each carried out once or repeated a number of times according to a given processing profile in the processing chamber. Each procedure involves an input into the processing chamber, an operation in the processing chamber and an output from the processing chamber by displacement of a piston (310). The at least three different procedures are sequentially chained one after the other to constitute an overall sequential operation in the processing chamber and its disposable set. A first application is incubation for binding magnetic beads with human blood cells or stem cells. A second application is transduction by which foreign genetic material is inserted into human blood cells or stem cells by a virus. A third application is reconditioning biological fluids to achieve reproducible concentration and volumes of blood cells or stem cells.
n), transmitting transportation profile data to one or more transportation devices, and transmitting thawing profile data to one or more thawing devices. The remote server is also capable of receiving detected data from the one or more freezers relating to the freezing of a sample in accordance with the freezing profile data, receiving detected data from the one or more transportation devices relating to the transportation of a sample in accordance with the transportation profile data, and receiving detected data from the one or more thawing machines relating to the thawing of a sample in accordance with the thawing profile data.
F25D 29/00 - Arrangement or mounting of control or safety devices
A01N 1/145 - Stationary or portable vessels generating cryogenic temperatures, e.g. liquid nitrogen baths
A01N 1/148 - Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving with provisions specially adapted for transporting
A01N 1/162 - Temperature processes, e.g. following predefined temperature changes over time
B01L 7/00 - Heating or cooling apparatusHeat insulating devices
H04L 67/125 - Protocols specially adapted for proprietary or special-purpose networking environments, e.g. medical networks, sensor networks, networks in vehicles or remote metering networks involving control of end-device applications over a network
A bioreactor system includes a vessel having a bottom floor, a flexible bioprocessing bag disposed within the vessel, and a flexible bladder positioned intermediate the bottom floor of the vessel and the bioprocessing bag. The flexible bladder is selectively inflatable to vary at least one of a geometry or configuration of the bioprocessing bag to provide for improved drainability or an increased turndown ratio for the bioreactor system.
A system comprising that includes a flow tube configured to provide a flow path through the flow tube. The system also includes a plurality of actuators distributed radially about the flow tube, wherein a first actuator of the plurality of actuators is configured to drive a first oscillation in a first plane and a second actuator of the plurality of actuators is configured to drive a second oscillation in a second plane. Further, the system includes a plurality of sensor sets disposed on the flow tube, wherein each sensor set comprises two or more sensors configured to sense the first oscillation, the second oscillation, or both.
Disclosed are bioreactor flasks (10) including a volume extending between a first volume end and a second volume end for the cultivation of cells or other microorganisms, said volume having a horizontal cross section area (CSA) which increases in a direction from the first volume end to the second volume end. The flask optionally includes a housing including a cylindrical lower portion (14) and an inverted truncated conical upper portion (16) which provides said increasing CSA. Disclosed also are arrays of flasks (10), supported in a tray for collective agitation.
A storage vial (100, 200) may include a vial body (110, 210) having a first end (111, 211) and a second end (112, 212) and defining an internal volume (113, 213) configured to contain a biological material (B) therein, a first valve (120, 220) positioned at the first end of the vial body, a second valve (130, 230) positioned at the second end of the vial body, a first conduit connector (160, 260) positioned at the first end of the vial body, and a second conduit connector (170, 270) positioned at the second end of the vial body. The resulting construction may allow for closed system direct transfer of biological material from the storage vial to another vessel using aseptic techniques.
The present application provides a means for differential diagnosis of Parkinson's disease and the clinically similar Parkinsonian disorders multiple system atrophy with predominantly Parkinsonian features (MSA-P) and progressive supranuclear palsy (PSP).
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
An inflatable bioreactor (110, 210) may include one or more sheets joined to form a bag (111, 211) including a top sheet (118, 218) and a bottom sheet (119, 219) formed from the one or more sheets and being inflatable to provide an internal volume (117, 217) suitable for retaining a volume of culture liquid (10) during flow of the culture liquid resulting from a rocking motion (R) of the bag, and one or more perturbing protrusions (116, 116', 116'', 216) extending upwardly from the bottom sheet toward, but not as far as, the top sheet and extending transversely to, or obliquely to, a direction of wave motion (W) of the culture liquid. The resulting construction may provide improved flow for low initial volumes of the culture liquid in the bag.
The invention relates to a a single-use flexible bioreactor bag comprising a rigid multiport plate sealed to a side wall of said bioreactor bag, wherein said multiport plate comprises a plurality of ports. The invention further relates to a method of manufacturing the bag and to a method of installing the bag in a rigid support vessel.
The present invention provides a method for the synthesis of an injectable composition comprising a [18F]-labelled pyridaben derivative that is advantageous over prior methods. In particular, the method of the present invention comprises a method of radiosynthesis that permits a more facile purification using solid phase extraction (SPE).
The present invention provides a method for the synthesis of an injectable composition comprising a [18F]-labelled pyridaben derivative that is amenable to automation. In particular, the method of the present invention comprises a method of purification carried out by means of solid phase extraction (SPE) alone.
The present invention relates to a method for collecting a biological sample, such as a forensic sample, the method comprising the steps of a) providing a swab including a handle wherein one tip or end of the handle is coated with fibres, such as polyester fibres, to form an absorbent flocked head, wherein the head having a surface area of 3-80 mm2 and wherein the swab head fits into a 10-200 µl volume reaction well/tube; b) collecting a biological sample comprising nucleic acid on the head by contact between the head and the sample, c) subjecting the nucleic acid in the sample to nucleic acid (NA)amplification. The invention also relates to a collection swab for use is said method.
The present invention provides a method for the synthesis of an injectable composition comprising a [18F]-labelled pyridaben derivative that is amenable to automation. In particular, the method of the present invention comprises a method of purification carried out by means of solid phase extraction (SPE) alone.
The present invention relates a method of monitoring an automated radiosynthesizer during a run and the radiosynthesizer having a number of individual activity detectors operably associated therewith. The method comprises the steps of recording S10 activity data from each activity detector; accessing S20 historic data from a data storage; detecting S30 precursor of yield drop in the recorded activity data based on the historic data; predicting (S40 yield when synthesizing a tracer with the radiosynthesizer based on the detected precursor of yield drop; and initiating S50 actions related to a level of predicted yield.
The present invention relates a method of monitoring an automated radiosynthesizer during a run and the radiosynthesizer having a number of individual activity detectors operably associated therewith. The method comprises the steps of recording S10 activity data from each activity detector; accessing S20 historic data from a data storage; detecting S30 precursor of yield drop in the recorded activity data based on the historic data; predicting (S40 yield when synthesizing a tracer with the radiosynthesizer based on the detected precursor of yield drop; and initiating S50 actions related to a level of predicted yield.
The present invention provides a method for the synthesis of an injectable composition comprising a [18F]-labelled pyridaben derivative that is advantageous over prior methods. In particular, the method of the present invention comprises a method of radiosynthesis that permits a more facile purification using solid phase extraction (SPE).
